Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Taisho Pharmaceutical Holdings Co., Ltd. is a leading Japanese pharmaceutical company specializing in over-the-counter (OTC) drugs and prescription medications. Its competitive position is strengthened by a robust product portfolio, including the well-known Alinamin brand, and a significant presence in the Asian markets, particularly Japan and Southeast Asia.
Taisho generates revenue primarily through the sale of OTC drugs, which benefit from strong brand recognition and consumer loyalty. The company leverages its extensive distribution network in Japan and neighboring regions to maintain pricing power and market share. Its focus on research and development allows it to innovate and expand its product offerings.
Sales growth of Alinamin and other flagship OTC products
Regulatory approvals for new prescription drugs
Market expansion in Southeast Asia
Changes in consumer healthcare spending patterns
Regulatory changes affecting drug approvals and pricing
Technological disruption in drug development processes
Intense competition from generic drug manufacturers
Emerging biotech firms with innovative therapies
Potential liquidity issues due to negative free cash flow
Dependence on successful product launches to sustain growth
moderate - The company's performance is somewhat linked to consumer spending on healthcare products, which can fluctuate with economic conditions.
Low - Taisho has minimal debt, so rising interest rates do not significantly impact financing costs or valuation multiples.
minimal - The company maintains a debt/equity ratio of 0.00, indicating strong liquidity and minimal reliance on credit.
growth - Investors are likely attracted to Taisho's strong revenue growth and expansion potential in emerging markets.
moderate - The stock has shown significant returns recently, indicating some volatility, but its fundamentals remain strong.
